Skip to main content
. 2016 Jan 28;20(4):678–687. doi: 10.1111/jcmm.12777

Figure 2.

Figure 2

Aggrecanase activity and detection of GAGs and COMP degradation products in Fn‐fs‐induced OA‐SF in the presence of VIP or CRF. (A) Aggrecanase activity was measured in culture supernatants by an Aggrecanase Activity ELISA kit after 24 hrs of treatment. A mean of duplicate determinations was obtained for each HD (n = 4) (left) and OA (n = 5) (right). (B) GAGs in the supernatants from cartilage‐SF co‐cultures were detected after 14 days of treatment using a Blyscan™ Sulfated Glycosaminoglycan Assay. A mean of duplicate determinations was obtained for each HD (n = 3) (left) and OA (n = 3) (right). (C) COMP degradation products in the supernatants from cartilage‐SF co‐cultures were detected after 14 days of treatment using a Quantikine® Human COMP Immunoassay. A mean of triplicate determinations was obtained for each HD (n = 3) (left) and OA (n = 3) (right). Dashed lines represent the untreated condition. Values are presented as the percentage of untreated cells (mean ± S.E.M.). Significant differences between treatments are indicated by a bar with the P‐value above.